Achira
Private Company
Funding information not available
Overview
Achira is a private, pre-revenue AI/ML biotech founded in 2018, developing a novel computational platform for drug discovery. The company has secured $33M in funding from notable investors including Dimension, Amplify Partners, NVIDIA NVentures, and Compound. Its core technology aims to overcome the limitations of traditional biomolecular simulation and pure machine learning models by creating a new class of foundation simulation models. This platform is designed to generate high-fidelity synthetic data to enable generative AI for therapeutic compound design.
Technology Platform
Atomistic foundation simulation models blending geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced potentials and generative models for drug discovery.
Opportunities
Risk Factors
Competitive Landscape
Achira competes in the rapidly evolving AI-driven drug discovery space against pure-play AI biotechs (e.g., Recursion, Exscientia), tech giants with biology efforts (e.g., Google's Isomorphic Labs/DeepMind), and established computational chemistry software providers. Its differentiation lies in its hybrid physics-ML approach focused on high-fidelity simulation and synthetic data generation, a niche with fewer direct competitors but high technical barriers.